Comparative in vitro activities of six new fluoroquinolones and other oral antimicrobial agents against Campylobacter pylori

Simor, Andrew E.; Ferro, Sayonara da Luz; Low, Donald E.

doi:10.1128/aac.33.1.108

Cited by 26 publications

(9 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tests of inhibition of other diverse organisms for up to 21 days have been reported (7,26,35,42,71). Because the drug levels in the growth media were not measured throughout the 14-day test period in this study, it was not possible to determine from the inhibition curves whether a postantibiotic effect or a sub-MIC (inhibitory) effect occurred (21,83).…”

Section: Discussionmentioning

confidence: 99%

Inhibition of Nanobacteria by Antimicrobial Drugs as Measured by a Modified Microdilution Method

Çiftçioğlu

Miller-Hjelle

Hjelle

et al. 2002

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Compounds from 16 classes of antimicrobial drugs were tested for their abilities to inhibit the in vitro multiplication of nanobacteria (NB), a newly discovered infectious agent found in human kidney stones and kidney cyst fluids from patients with polycystic kidney disease (PKD). Because NB form surface calcifications at physiologic levels of calcium and phosphate, they have been hypothesized to mediate the formation of tissue calcifications. We describe a modified microdilution inhibitory test that accommodates the unique growth conditions and long multiplication times of NB. This modified microdilution method included inoculation of 96-well plates and determination of inhibition by periodic measurement of the absorbance for 14 days in cell culture medium under cell culture conditions. Bactericidal or bacteriostatic drug effects were distinguished by subsequent subculture in drug-free media and monitoring for increasing absorbance. NB isolated from fetal bovine serum (FBS) were inhibited by tetracycline HCl, nitrofurantoin, trimethoprim, trimethoprim-sulfamethoxazole, and ampicillin at levels achievable in serum and urine; all drugs except ampicillin were cidal. Tetracycline also inhibited multiplication of isolates of NB from human kidney stones and kidney cyst fluids from patients with PKD. The other antibiotics tested against FBS-derived NB either had no effect or exhibited an inhibitory concentration above clinically achievable levels; the aminoglycosides and vancomycin were bacteriostatic. Antibiotic-induced morphological changes to NB were observed by electron microscopy. Bisphosphonates, aminocaproic acid, potassium citrate-citric acid solutions, and 5-fluorouracil also inhibited the multiplication of NB in a cidal manner. Insights into the nature of NB, the action(s) of these drugs, and the role of NB in calcifying diseases may be gained by exploiting this in vitro inhibition test system.

show abstract

Section: Discussionmentioning

confidence: 99%

Inhibition of Nanobacteria by Antimicrobial Drugs as Measured by a Modified Microdilution Method

Çiftçioğlu

Miller-Hjelle

Hjelle

et al. 2002

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…In vitro, a number of antibiotics, including P-lactams, macrolides, and quinolones, have been known to be highly active against H. pylori (1,8,10,13,22,30,32,33,36). However, when tested as single agents in clinical studies, erythromycin (23), doxycycline (35), ofloxacin (5), ciprofloxacin (34), and norfloxacin (24) have not succeeded in eradicating H. pylori.…”

Section: Resultsmentioning

confidence: 99%

Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori

Iwahi

Satoh

Nakao

et al. 1991

Antimicrob Agents Chemother

269

156

View full text Add to dashboard Cite

The activities of various types of antiulcer agents against Helicobacter pylori (formerly called Campylobacter pylon) strains were determined by an agar dilution method. Among the compounds tested, two benzimidazole proton pump inhibitors, lansoprazole (AG-1749) and omeprazole, were found to have significant activities against this organism. The activity of lansoprazole was comparable to that of bismuth citrate, with MICs ranging from 3.13 to 12.5 ,ug/ml, and fourfold more potent than that of omeprazole. A major metabolite and two acid-converted rearrangement products of lansoprazole also exhibited good activities comparable or superior to that of the parent compound. Exposure to lansoprazole of H. pylori growing in a liquid medium led to an extensive loss of viability without a reduction in culture turbidity and produced an aberrant bacterial morphology characterized by the irregular constriction of cells and the collapse of cell surface structures. The antibacterial activity of lansoprazole and its related compounds was selective against H. pylori; common aerobic and anaerobic bacteria and Campylobacterjejuni were not inhibited by 100 ,ug/ml.

show abstract

“…Using a multipoint inoculator, 3.3 μl of the suspension (i.e., ≈ 2.5 × 10 5 organisms per spot) were inoculated on freshly prepared agar plates containing either one or both test substances as well as on control plates with DMSO alone. Plates were incubated for 48 hours in a microaerophilic atmosphere, and MICs determined as described [14]. For azithromycin, no specific breakpoints for H. pylori have been established.…”

Section: Methodsmentioning

confidence: 99%

Combined Activity of Azithromycin and Lansoprazole Against Helicobacter pylori

Trautmann¹,

Riediger²,

Möricke³

et al. 1999

Helicobacter

View full text Add to dashboard Cite

show abstract

Comparative in vitro activities of six new fluoroquinolones and other oral antimicrobial agents against Campylobacter pylori

Cited by 26 publications

References 17 publications

Inhibition of Nanobacteria by Antimicrobial Drugs as Measured by a Modified Microdilution Method

Inhibition of Nanobacteria by Antimicrobial Drugs as Measured by a Modified Microdilution Method

Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori

Combined Activity of Azithromycin and Lansoprazole Against Helicobacter pylori

Contact Info

Product

Resources

About